摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Octahydro-1H-5,8-epoxy-2-benzopyran-3-ol | 74868-25-0

中文名称
——
中文别名
——
英文名称
Octahydro-1H-5,8-epoxy-2-benzopyran-3-ol
英文别名
4,11-dioxatricyclo[6.2.1.02,7]undecan-5-ol
Octahydro-1H-5,8-epoxy-2-benzopyran-3-ol化学式
CAS
74868-25-0
化学式
C9H14O3
mdl
——
分子量
170.21
InChiKey
QHTLROWUHMIFHR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    Octahydro-1H-5,8-epoxy-2-benzopyran-3-ol 、 Iodo-[3-(oxan-2-yloxy)propyl]-triphenyl-lambda5-phosphane 生成 [(1R,2S,3R,4R)-3-[(Z)-5-(oxan-2-yloxy)pent-2-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]methanol
    参考文献:
    名称:
    GORDON, ERIC M.;VARMA, RAVI K.
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease
    申请人:E.R. SQUIBB & SONS, INC.
    公开号:EP0403090A1
    公开(公告)日:1990-12-19
    7-Oxabicycloheptane imidazole prostaglandin analogs are provided which are useful in treating thrombotic and vasospastic disease and have the structural formula wherein m is 1, 2 or 3; n is 1, 2 or 3 and p is 1, 2 or 3; R is C02H, CO2lower alkyl, CO2alkali metal, CONHS02 R2 (wherein R2 is lower alkyl or aryl) or 5-tetrazolyl; A is CHOH, C=O, (wherein R3 is H or lower alkyl), or a single bond; R, is lower alkyl, aryl, cycloalkyl or H, R1 can be H only when A is a single bond.
    7-氧杂双环庚烷咪唑前列腺素类似物可用于治疗血栓性疾病和血管痉挛性疾病,其结构式为 其中m为1、2或3;n为1、2或3,p为1、2或3;R为C02H、CO2低级烷基、 碱属、CONHS02 R2(其中R2为低级烷基或芳基)或5-四唑基;A为CHOH、C=O、 (其中 R3 为 H 或低级烷基)或单键;R 为低级烷基、芳基、环烷基或 H,R1 只有在 A 为单键时才可以是 H。
  • 7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases
    申请人:E.R. SQUIBB & SONS, INC.
    公开号:EP0447188A2
    公开(公告)日:1991-09-18
    7-Oxabicycoheptane imidazole prostaglandin analogs are provided which are useful in treating thrombotic and vasospastic disease and have the structural formula wherein m is 0, 1, 2, 3 or 4; n is 1, 2 or 3; and p is 1, 2 or 3; Z is -CH=CH-, -CH2CH2- or wherein Y is 0 or a single bond ; R is C02H, CO2lower alkyl, C02alkali metal, CONHS02R2 (wherein R2 is lower alkyl or aryl) or -CH2-5-tetrazolyl; A is CHOH, C=O, (wherein R3 is H or lower alkyl), or a single bond ; R1 is lower alkyl, aryl, cycloalkyl or H, R1 can be H only when A is a single bond.
    提供了可用于治疗血栓性和血管痉挛性疾病的 7-氧杂双环庚烷咪唑前列腺素类似物,其结构式为 其中m是0、1、2、3或4;n是1、2或3;p是1、2或3;Z是-CH=CH-、- -或- -。 其中 Y 是 0 或单键;R 是 C02H、CO2lower 烷基、C02 碱属、CONHS02R2(其中 R2 是低级烷基或芳基)或 -CH2-5-四唑基;A 是 CHOH、C=O、 (其中 R3 为 H 或低级烷基)或单键;R1 为低级烷基、芳基、环烷基或 H,只有当 A 为单键时,R1 才可以是 H。
  • US4220594A
    申请人:——
    公开号:US4220594A
    公开(公告)日:1980-09-02
  • US4977174A
    申请人:——
    公开号:US4977174A
    公开(公告)日:1990-12-11
查看更多

同类化合物

马桑宁内酯 薁并[6,5-b]呋喃-2,4-二酮,十氢-5-(3-羟基丙氧基)-3a,4a-二甲基- 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 呋喃并[4,3,2-ij][2]苯并吡喃-2,7-二酮,2a,3,4,6,8a,8b-六氢-6-甲基-5-[(1S)-1,3,3-三甲基环己基]-,(2aR,6R,8aS,8bR)- 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 (3aα,3bβ,6aβ,7aα)-(+/-)-hexahydro-6-hydroxy-3a-(phenylmethyl)difuro<2,3-b:3',4'-d>furan-2(3H)-one (2R,3aS,4S,6S,7aR)-3a-benzyloxy-6-ethynyl-2-methoxy-4-p-methoxybenzyloxyhexahydrofuro[2,3-b]pyran (1R,2S,6S,7S)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester N3,5'-Cyclo-2',3'-O-isopropyliden-8-oxyguanosin (3aR,4aR,7aS,8aS)-2-Thioxo-hexahydro-furo[3',4':4,5]benzo[1,2-d][1,3]dioxol-5-one 9-(3',5'-O-Isopropyliden-2-keto-β-D-xylofuranosyl)-adenin (1aR,1bS,4aS,5aS)-1a-Isopropyl-hexahydro-1,4-dioxa-cyclopropa[a]pentalen-3-one [(3aR,4S,6R,7S,7aR)-7-acetyloxy-2-oxo-4-phenylsulfanyl-3,3a,4,6,7,7a-hexahydropyrano[3,4-d][1,3]oxazol-6-yl]methyl acetate (2R,3R,3aS,6R,7R,7aR)-7-azido-6-methoxy-2-phenylsulfanyl-hexahydrofuro[3,2-b]pyran-3-ol 7-Dihydroxymethyl-O1,O2-isopropyliden-3,7-anhydro-6-desoxy-D-glucofuranose (1S,2S,6S,7R)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester (2R,3S)-2-Methyl-4-oxo-oxetane-3-carboxylic acid (1R,5S)-6-methylene-3-oxo-bicyclo[3.2.1]oct-1-ylmethyl ester 3-C-(3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranosyl)-1-propene (2R,4aR,5aS,8aS,9S,9aR)-5a-methoxy-7-oxo-2-phenyloctahydrofuro[2',3':5,6]pyrano[3,2-d][1,3]dioxin-9-yl acetate (4R,5E,7R,9S,10S,11E,14S)-9-((benzyloxy)methoxy)-4,10-bis((tert-butyldimethylsilyl)oxy)-7-(dimethoxymethyl)-14-(furan-3-yl)-6,12-dimethyloxacyclotetradeca-5,11-dien-2-one 3-Furan-3-yl-8-methyl-5-(4,5,6,7-tetrahydro-isobenzofuran-4-yl)-2,7-dioxa-bicyclo[3.2.1]octane methyl 2,3"-anhydro-4,6-O-benzylidene-3-C-[2,2-dihydroxyethyl]-α-D-glucopyranoside (3aR,5S,6S,7aR)-5-((R)-but-3-en-2-yl)-6-hydroxyhexahydro-2H-furo[3,2-b]pyran-2-one 7-(3-Furan-3-yl-8-methyl-2,7-dioxa-bicyclo[3.2.1]oct-5-yl)-1,3,4,5,6,7-hexahydro-isobenzofuran-1-ol